{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:57:49Z","timestamp":1755223069776,"version":"3.43.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Statistics"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Studies incorporating randomized controlled trial (RCT) controls with real\u2010world (RW) patients face concerns of selection bias and unmeasured confounding. To evaluate two methods (Match, Test\u2010then\u2010Pool [MTP] and Matching and Bias Adjustment [MBA]) to construct a hybrid control arm using concurrent RCT control patients and trial\u2010eligible RW patients from the CorEvitas Rheumatoid Arthritis (RA) Registry to replicate the treatment effect obtained from the original RCT. The measures considered estimate the effect of baricitinib on the proportion achieving 20% improvement in American College of Rheumatology response (ACR20) and change in disease activity (Clinical Disease Activity Index, CDAI) for patients with moderately to severely active rheumatoid arthritis. Patients included RCT treated (<jats:italic>n<\/jats:italic>\u2009=\u2009102), a 50% random sample of the RCT control (<jats:italic>n<\/jats:italic>\u2009=\u200949), and trial\u2010eligible RW (<jats:italic>n<\/jats:italic>\u2009=\u2009359). MTP used optimal propensity score (PS) matching to replace half of the RCT control group with a comparable RW control group (<jats:italic>n<\/jats:italic>\u2009=\u200949) and tested for differences between RCT and RW control outcomes before combining into the hybrid control arm for analysis. MBA leveraged 3 sets of optimal PS matches to identify a RW control group and adjusted for residual differences in outcomes between RCT and RW controls during analysis when creating the hybrid control arm. Optimal matching produced a matched RW cohort with satisfactory balance on the majority of key covariates compared to RCT participants. Using MTP, the odds ratio (OR) for ACR20 from covariate adjusted modeling was 4.71 (95% confidence interval [CI] 2.51, 9.15). Using MBA, ACR20 treatment effect from bias and covariate adjusted modeling was 4.76 (2.10, 10.81). For reference, the OR for the treatment difference of ACR20 for the trial\u2010eligible population was 3.81 (2.13, 6.95) and was 4.74 (2.32, 10.00) for the RCT population with 50% sample of controls. With MTP with covariate adjustment, the treatment effect of mean CDAI change was \u22128.96 (\u221212.58, \u22125.35). For MBA with bias and covariate adjustment, the treatment effect of mean CDAI change was \u22129.85 (\u221215.16, \u22125.02). In the original RCT, the mean CDAI change was \u22128.88 (\u221212.58, \u22125.18) and for the RCT population with 50% sample of controls, the mean CDAI change was \u221210.10 (\u221214.46, \u22125.74). With both hybrid control methods using the combination of well\u2010matched RWD and RCT control patients, we replicated the Phase IIb trial results.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> Data were used from Eli Lilly and Company's clinical trial (NCT01185353) and the CorEvitas Rheumatoid Arthritis Registry (NCT01402661), both registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link><\/jats:p>","DOI":"10.1002\/pst.70020","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T11:22:40Z","timestamp":1752405760000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Applying Bias Correction Methods to Build Hybrid Controls Using Real\u2010World Patients for a Phase <scp>IIb<\/scp> Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis"],"prefix":"10.1002","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3511-4078","authenticated-orcid":false,"given":"Heather J.","family":"Litman","sequence":"first","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin M.","family":"Sheffield","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana","family":"Pugach","sequence":"additional","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7131-562X","authenticated-orcid":false,"given":"Mingyang","family":"Shan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lakin","sequence":"additional","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanglin Lin","family":"Cui","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie R.","family":"Harrold","sequence":"additional","affiliation":[{"name":"CorEvitas, LLC  Waltham Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4975"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1723"},{"key":"e_1_2_8_4_1","unstructured":"United States Department of Health and Human Services Food and Drug Administration \u201cConsiderations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products: Guidance for Industry \u201d 2023 https:\/\/www.fda.gov\/media\/164960\/download."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2913"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-26328-6_12"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12561-022-09334-w"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2914"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33192-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2196\/43484"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2120"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S242097"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100446"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1332-x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpr025"},{"key":"e_1_2_8_16_1","unstructured":"United States Department of Health and Human Services Food and Drug Administration \u201cData Standards for Drug and Biological Product Submissions Containing Real\u2010World Data: Guidance for Industry \u201d 2023 https:\/\/www.fda.gov\/media\/153341\/download."},{"key":"e_1_2_8_17_1","unstructured":"United States Department of Health and Human Services Food and Drug Administration \u201cReal\u2010World Data: Assessing Registries to Support Regulatory Decision\u2010Making for Drug and Biological Products: Guidance for Industry \u201d 2023 https:\/\/www.fda.gov\/media\/154449\/download."},{"key":"e_1_2_8_18_1","unstructured":"C.Gao S.Yang M.Shan et\u00a0al. \u201cIntegrating Randomized Placebo\u2010Controlled Trial Data With External Controls: A Semiparametric Approach With Selective Borrowing \u201d arXiv Preprint arXiv: 2306. 166642 2023."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"issue":"5","key":"e_1_2_8_20_1","first-page":"S172","article-title":"The CORRONA Database","volume":"23","author":"Kremer J. M.","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1589"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3102\/1076998607306078"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380106"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.02.018"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10618600.1993.10474623"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696"},{"key":"e_1_2_8_28_1","unstructured":"L.WuandS.Yang \u201cIntegrative R\u2010Learner of Heterogeneous Treatment Effects Combining Experimental and Observational Studies \u201dinProceedings of the 1st Conference on Causal Learning and Reasoning PMLR 140 1\u2013S5 2022."},{"key":"e_1_2_8_29_1","unstructured":"Y.Cheng L.Wu andS.Yang \u201cEnhancing Treatment Effect Estimation: A Model Robust Approach Integrating Randomized Experiments and External Controls Using the Double Penalty Integration Estimator \u201d 2023UAI (39th Conference on Uncertainty in Artificial Intelligence)."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2297"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2841"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.101000"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_8_34_1","first-page":"267","volume-title":"Proceedings of the Second International Symposium on Information Theory","author":"Akaike H.","year":"1973"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10618600.1993.10474623"}],"container-title":["Pharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.70020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T10:14:35Z","timestamp":1754907275000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pst.70020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/pst.70020"],"URL":"https:\/\/doi.org\/10.1002\/pst.70020","archive":["Portico"],"relation":{},"ISSN":["1539-1604","1539-1612"],"issn-type":[{"type":"print","value":"1539-1604"},{"type":"electronic","value":"1539-1612"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"2025-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70020"}}